 PITTSBURGH, Jan. 18, 2023 GLOBE NEWSWIRE Krystal Biotech, Inc. the Company NASDAQ: KRYS, a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the European Commission has granted orphan designation for KB407 for the treatment of Cystic Fibrosis CF. KB407 is an investigational, redosable gene therapy ... The post Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatmen... 